TIDMPRM

RNS Number : 9487V

Proteome Sciences PLC

19 April 2021

19 April 2021

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Director/PDMR Shareholding

The Company has received notification from Roger McDowell, a Director of the Company, that on 16 April 2021 he purchased 900,000 Ordinary Shares in the Company at a price of 5.00p per share. Roger McDowell now holds 3,400,000 Ordinary Shares in the Company, which represents approximately 1.15% of the issued share capital of the Company.

The below notification is made in accordance with the requirements of the UK Market Abuse Regulation.

 
 1.   Details of the person discharging managerial responsibilities/person 
       closely associated 
 a)   Name:                                      Roger McDowell 
     -----------------------------------------  ----------------------------------- 
      Reason for the notification 
     ------------------------------------------------------------------------------ 
 a)   Position/status:                           Non-Executive Director 
     -----------------------------------------  ----------------------------------- 
 b)   Initial notification/Amendment:            Initial Notification 
     -----------------------------------------  ----------------------------------- 
      Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------------------ 
 a)   Name:                                      Proteome Sciences Plc 
     -----------------------------------------  ----------------------------------- 
 b)   LEI:                                       213800Q62ICXANKU2986 
     -----------------------------------------  ----------------------------------- 
      Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ------------------------------------------------------------------------------ 
 a)   Description of the financial instrument,   Ordinary Shares of 1p 
       type of instrument:                        nominal value 
       Identification code:                       GB0003104196 
     -----------------------------------------  ----------------------------------- 
 b)   Nature of the transaction:                 Purchase of Ordinary Shares 
     -----------------------------------------  ----------------------------------- 
 c)   Price(s) and volume(s):                      Price(s)   Volume(s) 
                                                    5.00p      900,000 
                                                              ---------- 
     -----------------------------------------  ----------------------------------- 
 d)   Aggregated information:                    Single transaction as 
        *    Aggregated volume:                   in 4 c) above Average   Volume(s) 
                                                    Price 
                                                   5.00p     900,000 
        *    Price:                                         ---------- 
     -----------------------------------------  ----------------------------------- 
 e)   Date of the transaction:                    16 April 2021 
     -----------------------------------------  ----------------------------------- 
 f)   Place of the transaction:                  London Stock Exchange, 
                                                  AIM (XLON) 
     -----------------------------------------  -----------------------------------

For further information please contact:

 
 Proteome Sciences plc 
 Mariola Soehngen M.D., Chief Executive Officer   Tel: +44 (0)20 7043 2116 
  Dr Ian Pike, Chief Scientific Officer 
 Allenby Capital Limited (AIM Nominated Adviser & Broker) 
 John Depasquale / Jeremy Porter - Corporate      Tel: +44 (0) 20 3328 5656 
  Finance 
  Tony Quirke - Sales and Corporate Broking

About Proteome Sciences plc. ( www.proteomics.com )

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant(R) and TMT(R)MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator(TM) provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHSFEFMUEFSEEL

(END) Dow Jones Newswires

April 19, 2021 12:25 ET (16:25 GMT)

Proteome Sciences (LSE:PRM)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Proteome Sciences.
Proteome Sciences (LSE:PRM)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Proteome Sciences.